Cisplatin + AZD1775
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Triple-negative Metastatic Breast Cancer
Conditions
Triple-negative Metastatic Breast Cancer
Trial Timeline
Jan 18, 2017 → Nov 30, 2020
NCT ID
NCT03012477About Cisplatin + AZD1775
Cisplatin + AZD1775 is a phase 2 stage product being developed by AstraZeneca for Triple-negative Metastatic Breast Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT03012477. Target conditions include Triple-negative Metastatic Breast Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03012477 | Phase 2 | Completed |
Competing Products
20 competing products in Triple-negative Metastatic Breast Cancer